Funding
← Back to your selection

DCVC

Activity from announced rounds

Activity in this selectionOct 17, 2026 · AI · Jul 20, 2026

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
3
Confirmed lead rounds
1
1 roles undisclosed
New companies
2
First participation on record · 1 follow-on
Funding in participating rounds
$1B
3 disclosed · full round size, not this investor’s share

By stage

Seed2
Series A1

By primary sector

AI3

By country

United States2
United Kingdom1

Rounds

3 in this selection
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$40MSeed
Lead
Callosum

Software infrastructure allowing AI workloads to run across different chips and models

$100MSeed
Role not disclosed